Transcatheter Valve Repair System for MR and TR Patients Enables Precise Navigation and Implant Delivery
By HospiMedica International staff writers Posted on 24 Aug 2022 |
A new transcatheter valve repair system for the treatment of mitral and tricuspid regurgitation (MR and TR) is designed to enable precise navigation and implant delivery.
Edwards Lifesciences’ (Newbury, Berkshire, UK) PASCAL Precision transcatheter valve repair system is utilized in the treatment of patients with MR and TR, through a single delivery system. The PASCAL Precision system includes PASCAL and PASCAL Ace implants, which feature independent grasping, atraumatic clasp and closure, and implant versatility including the ability to elongate and navigate complex anatomy.
The PASCAL platform is designed for predictable capture, positioning and release in patients with MR. The PASCAL Ace implant expands treatment options, allowing physicians to tailor the procedure to their needs. PASCAL Ace provides a narrow profile designed to improve ease of subvalvular navigation. The PASCAL Ace implant is designed for even challenging TRs, instilling confidence to help more patients. PASCAL Ace provides a narrow implant profile designed to improve ease of subvalvular navigation.
Designed to enhance experience with the PASCAL platform, the PASCAL Stabilizer Rail System comes with multiple stabilizers to advance, retract, and torque catheters. Secure stabilizers to allow for stable and incremental movements and fine adjustments. Additionally, ease-of-use enhancements help reduce unintended catheter movements throughout the procedure. The PASCAL Precision transcatheter valve repair system has received CE Mark for the treatment of MR and TR. The PASCAL Precision system is one of multiple transcatheter repair or replacement therapies in development by Edwards that are designed to address mitral and tricuspid valve diseases.
"Delivering the PASCAL Precision system to clinicians in Europe marks another significant step in our partnership with physicians who treat the large population of patients with mitral and tricuspid valve disease," said Bernard J. Zovighian, Edwards' corporate vice president, transcatheter mitral and tricuspid therapies. "Edwards has a long history of innovation, and the significant advancements in the PASCAL Precision system are designed to improve clinicians' ability to provide positive outcomes for patients with both MR and TR."
Latest Critical Care News
- AI Brain-Age Estimation Technology Uses EEG Scans to Screen for Degenerative Diseases
- Wheeze-Counting Wearable Device Monitors Patient's Breathing In Real Time
- Wearable Multiplex Biosensors Could Revolutionize COPD Management
- New Low-Energy Defibrillation Method Controls Cardiac Arrhythmias
- New Machine Learning Models Help Predict Heart Disease Risk in Women
- Deep-Learning Model Predicts Arrhythmia 30 Minutes before Onset
- Breakthrough Technology Combines Detection and Treatment of Nerve-Related Disorders in Single Procedure
- Plasma Irradiation Promotes Faster Bone Healing
- New Device Treats Acute Kidney Injury from Sepsis
- Study Confirms Safety of DCB-Only Strategy for Treating De Novo Left Main Coronary Artery Disease
- Revascularization Improves Quality of Life for Patients with Chronic Limb Threatening Ischemia
- AI-Driven Prediction Models Accurately Predict Critical Care Patient Deterioration
- Preventive PCI for High-Risk Coronary Plaques Reduces Cardiac Events
- AI Diagnostic Tool Guides Rapid Diagnosis and Prediction of Sepsis
- World's First AI-Powered Sepsis Alert System Detects Sepsis in One Minute
- Smartphone Magnetometer Uses Magnetized Hydrogel to Measure Biomarkers for Disease Diagnosis